Genomics

Strong Q2 results, pivotal deals with AstraZeneca and MSK, and a clear path to profitability signal SOPHiA GENETICS is converting its AI platform into market leadership.

MGI Tech's strategic alliance with NCSTAR in Queensland is set to accelerate medical breakthroughs by providing a full suite of cutting-edge 'multi-omics' tools.

Human Longevity's new low-cost whole genome sequencing promises predictive health for all, but its true power lies in its AI and a vast new data asset.

With $100M in total funding, bioinformatics firm Inocras plans to challenge U.S. precision oncology leaders by leveraging its whole-genome sequencing success in Asia.

BGLC aims to upend cancer monitoring in emerging markets with a low-cost liquid biopsy. But can a micro-cap execute on this billion-dollar vision?

A 49% stock plunge and a major acquisition write-down have thrust GeneDx into legal turmoil. We deconstruct the securities fraud claims and what they reveal.

Labcorp's new direct-to-consumer genetic panel promises early risk detection. But does it create a new set of challenges for patients and doctors?

After a disastrous Q2 report and lowered guidance, all eyes are on Azenta's August 5th call. We dissect the key metrics and strategic shifts to watch.

City of Hope's new trial, funded by ARPA-H, uses DNA mapping to predict immunotherapy success, promising a new era of personalized care for lung cancer.

Beyond an impressive metric, DNAnexus's high customer trust validates its strategic pivot to become the essential AI backbone for the precision health revolution.

EHE Health is now offering GRAIL's Galleri test, a move that signals a major shift in corporate wellness but raises key questions about cost and access.

An award-winning platform is bringing scientific scrutiny to the supplement aisle. Can this push for transparency force a new standard of accountability?

Parse Biosciences, QIAGEN's strategic acquisition, just partnered with Australia's Garvan Institute. It's more than science—it's a calculated play to win.

Bruker's acquisition of the DISQVER® platform signals a major shift in infection diagnostics, promising to identify thousands of pathogens in hours, not days.

A German court ruling against genomics giant Illumina is more than a legal win for a rival; it's a shockwave hitting the core of biotech innovation and biosecurity.

A new $4,000-a-year service combines genomics and AI for proactive health. But as SONATA launches, it exposes the deep divide in our digital future.

A new deal between genomics giant Illumina and startup Bifrost Biosystems isn't just a business transaction. It’s a strategic play to rewire the very process of drug discovery.

GeneCentric's ExpressCT Rewind™ uses fragmentomics to mine gene expression data from old liquid biopsies, offering a cost-effective way to find new biomarkers.

AstraZeneca's new deal with genomics firm Helix isn't just a partnership; it's a bet on a future where drug discovery is driven by massive data vaults.